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A multinational observational study identifying primary care
patients at risk of overestimation of asthma control
Vicky Kritikos1,2*, David Price 3,4,5, Alberto Papi6, Antonio Infantino7, Bjorn Ställberg8, Dermot Ryan 3,9, Federico Lavorini 10,
Henry Chrystyn11, John Haughney 12, Karin Lisspers8, Kevin Gruffydd-Jones13, Miguel Román Rodríguez14,
Svein Høegh Henrichsen15, Thys van der Molen16, Victoria Carter 3,4 and Sinthia Bosnic-Anticevich1,17,18
Factors related to the discrepancy between patient-perceived and actual disease control remain unclear. Identifying patients at risk
of overestimation of asthma control remains elusive. This study aimed to (i) investigate the relationship between patient-reported
and actual level of asthma control (ii), compare the characteristics between patients who believe their asthma is well controlled that
accurately report ‘well-controlled’ asthma with those that do not, and (iii) identify factors associated with inaccurately reported
‘well-controlled’ asthma. A historical, multinational, cross-sectional study using data from the iHARP (initiative Helping Asthma in
Real-life Patients) review service for adults with asthma prescribed ﬁxed-dose combination therapy. Data from 4274 patients were
analysed. A major discrepancy between patient-reported and Global Initiative for Asthma deﬁned asthma control was detected;
71.1% of patients who reported ‘well-controlled’ asthma were inaccurate in their perception despite receiving regular maintenance
therapy. Signiﬁcant differences were noted in age, gender, body mass index, education level, medication use, side effects, attitudes
to preventer inhaler use, inhaler technique review and respiratory specialist review between patients who accurately reported ‘well-
controlled’ asthma and those who did not. Independent risk factors associated with inaccurately reported ‘well-controlled’ asthma
were: having taken a maximum of 5–12 puffs or more of reliever inhaler on at least one day within the previous 4 weeks; being
female; having seen a respiratory specialist more than a year ago (rather than in the previous year); and having required oral
corticosteroids for worsening asthma in the previous year. The study highlighted the signiﬁcant hidden burden associated with
under-recognition of poor asthma control, on the part of the patient and the need for targeted interventions designed to address
the continuing discrepancy between perceived and actual disease control.
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INTRODUCTION
Asthma is one of the most common chronic conditions world-
wide,1 affecting ~30 million people in Europe and more than 5
million people in the United Kingdom (UK).2 Despite the existence
of a global strategy for asthma management,3 and availability of
national guidelines and effective treatments,4 rates of poor
asthma control remain high worldwide.5–20 Poor asthma control
reduces patients’ quality of life and productivity, increases health
care utilisation and the risk of exacerbations and mortality.6,8,21
Further, poor asthma control poses a greater economic burden on
individuals, communities and health care systems than controlled
disease.22,23
When it comes to disease control, the patient experience of
symptoms over time is extremely important. Unfortunately, this is
one of the great challenges in asthma management. Many
patients who consider their asthma to be ‘well controlled’ often
overestimate their actual level of asthma control.9,19,24,25 While a
discrepancy between patient-perceived and actual disease control
is frequently reported, the reasons for and the factors related to
this disparity remain unclear. Identifying patients at risk of
overestimation of asthma control remains elusive.
The ramiﬁcations of overestimating level of disease control on
the part of the patient are far-reaching. Many patients who
mistakenly consider their asthma to be ‘well controlled’ often
accept their symptoms as being part of the ‘norm’ of having
asthma and are unlikely to seek asthma-related information,
education or care from health care practitioners (HCPs).26 Further,
since guideline treatment options are based on patient-reported
symptoms,3,4 appropriate treatment may not be prescribed if a
patient fails to recognise and report poorly controlled symptoms
to their HCP.27 Patients who do not voice their concerns or under-
report troublesome symptoms run the risk of under-treatment and
the perpetuation of poor asthma control and a potential increased
future risk of adverse outcomes.12 This under-reporting of
symptoms by patients also emphasises the need for more
objective measures such as spirometry and symptom question-
naires in clinical practice.
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In an attempt to improve rates of well-controlled asthma, a
number of studies have identiﬁed modiﬁable and unmodiﬁable
risk factors for poor asthma control across different patient
populations.28–32 While a broad range of risk factors, both clinical
and behavioural, have been identiﬁed, assessment of asthma
control continues to be based on patient-reported symptoms,
hence once again highlighting the importance of the relationship
between patient-reported and actual disease control among
patients in a real-life clinical setting.9,33 To date, little is known
about factors associated with overestimation of the level of
asthma control. From an HCP perspective, it seems critical to be
able to identify patients at risk of overestimating their level of
asthma control, and thus inaccurately reporting ‘well-controlled’
asthma. Insight into factors associated with inaccurately reported
‘well-controlled’ asthma may help HCPs’ tailor interventions to
patient proﬁles and help identify effective asthma management
strategies for the future. We hypothesised that factors associated
with inaccurately reported ‘well-controlled’ asthma among adults
with a current physician diagnosis of asthma are patient-related,
and some factors are potentially modiﬁable.
This research aimed to use patient data from the iHARP
(initiative Helping Asthma in Real-life Patients) database34 to gain
deeper insight into the discrepancy between perceived and actual
disease control. The speciﬁc objectives were to (i) investigate the
relationship between patient-reported and actual level of asthma
control, (ii) compare the demographic, clinical and attitudinal/
behavioural characteristics between patients who believe their
asthma is well controlled that accurately report ‘well-controlled’
asthma with those that overestimate their level of asthma control
and inaccurately report ‘well-controlled’ asthma and (iii) identify
factors associated with inaccurately reported ‘well-controlled’
asthma.
RESULTS
Patients
There were 4274 adult patients with asthma-prescribed FDC ICS/
LABA therapy in the iHARP database between June 2011 and
December 2014. The study cohort included 2574 (60.2%) from the
UK, 652 (15.3%) from the Netherlands, 527 (12.3%) from Spain, 403
(9.4%) from Italy, 62 (1.5%) from Sweden, 36 (0.8%) from Norway
and 20 (0.5%) from France. The mean (SD) age of patients was 50.9
(14.3) years, 2600 (60.8%) were females, 1416 (33.1%) were obese
(body mass index ≥30 kg/m2) and 553 (12.9%) were current
smokers.
Among the 4274 patients, 1296 (30.3%) patients had controlled
asthma, 1912 (44.7%) had partially controlled asthma and 1066
(25.0%) uncontrolled asthma using Global Initiative for Asthma
(GINA)-deﬁned criteria (Table 1). When asked about their asthma
in the past 4 weeks, 2582 (60.4%) patients believed their asthma
was ‘well controlled’. Of this subset of patients, only 745 (28.9%)
patients accurately reported ‘well-controlled’ asthma (Group A)
and 1837 (71.1%) inaccurately reported ‘well-controlled’ asthma
(Group B), that is, they overestimated their level of asthma control
(Table 1).
Of the 1692 (39.6%) patients who believed their asthma was
‘not well controlled’ in the past 4 weeks, 1141 (67.4%) accurately
reported ‘not-well-controlled’ asthma and 551 (32.6%) under-
estimated their level of asthma control (Table 1). The incidence of
accurately reported ‘well controlled’ asthma was signiﬁcantly
lower than that of accurately reported ‘not-well-controlled’ asthma
(28.9% vs. 67.4%, p= 0.010).
Characteristics of patients who inaccurately reported ‘well-
controlled’ asthma
Patients in Group B who overestimated their asthma control level,
that is, inaccurately reported ‘well-controlled’ asthma were
signiﬁcantly more likely to be older, female, obese, or lacking a
university degree than those in Group A who accurately estimated
‘well-controlled’ asthma (Table 2). In the week prior to iHARP data
collection, 34.2% of Group B patients experienced asthma
symptoms for >2 days, 466 (25.4%) indicated that symptoms
interfered with their daily activities, 526 (28.6%) had night
awakenings due to asthma and 769 (41.9%) used their relievers
≥3 times (Table 2), with 261 (14.2%) indicating they used their
relievers ≥10 times. In the 4 weeks prior to data collection, the
incidence of taking 5–12 puffs or more of reliever in one day was
signiﬁcantly higher among patients in Group B than those in
Group A (13.1% vs. 1.2%, p < 0.001) (Table 3). In addition, Group B
patients were signiﬁcantly more likely to report having experi-
enced acute exacerbations requiring short-term courses of oral
corticosteroids and asthma-related hospitalisations in the previous
year compared with patients in Group A (Table 3).
Patient-reported inhaler review by an HCP in the previous year,
oropharyngeal effects during the inspiration phase of preventer
inhaler use and side effects from asthma therapy were more
common among patients in Group B than those in Group A (Table 4).
Compared to patients in Group A, patients in Group B were
signiﬁcantly more likely to be in agreement that they need to take
their inhaler(s) in order for their asthma to be ‘well controlled’ and
were signiﬁcantly more likely to have been reviewed by a
respiratory specialist more than a year ago rather than in the
previous year (Table 4). The incidence of accurately reported ‘well-
controlled’ asthma was signiﬁcantly higher among patients who
had seen a respiratory specialist in the previous year than those
who had seen a respiratory physician more than a year ago (31.8%
vs. 20.8%, p < 0.001).
Factors associated with inaccurately reported ‘well-controlled’
asthma
Univariate logistic regression models were developed using
independent variables as risk factors for inaccurately reported
Table 1. GINA-deﬁned asthma control overall and by patient-reported level of asthma control.
GINA-deﬁned asthma controla Total, N (%) (N= 4274) Patient-reported level of asthma control (N= 4274)
Well controlled, n (%) (n= 2582) Not well controlled, n (%) (n= 1692)
Controlled 1296 (30.3) 745 (28.9) 551 (32.6)
Partially controlled 1912 (44.7) 1299 (50.3) 613 (36.2)
Uncontrolled 1066 (25.0) 538 (20.8) 528 (31.2)
Note: Data are shown as percentage of patients, N= 4274; patients who reported ‘well-controlled’ asthma, n= 2582, and those who reported ‘not-well-
controlled’ asthma, n= 1692
aGINA (Global Initiative for Asthma) criteria: daytime symptoms (>2 days/week); need reliever inhaler (>2 days/week); any limitation in daytime activity; any
night wakening due to asthma in the past week. The presence of these four criteria determined the asthma control level: none of the above (controlled); 1 or 2
of the above (partially controlled); 3 or 4 of the above (uncontrolled)
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‘well-controlled’ asthma. The univariate models considered all 12
variables (age group, gender, body mass index, education level,
highest number of puffs of reliever taken in one day, oral
corticosteroid use for worsening asthma, hospitalisation due to
asthma, inhaler review by an HCP, respiratory specialist review,
side effects from preventer inhaler use, oropharyngeal effects
during the inspiration phase and need to take inhaler(s) for
asthma to be well controlled), which were associated with
inaccurately reported ‘well-controlled’ asthma. The univariable
logistic regression results for the risk of inaccurately reported
‘well-controlled’ asthma are shown in Table 5. There were no
correlations between the univariate predictors; therefore, they
were subsequently included for analysis in the multivariate logistic
regression model. The multivariable logistic regression model was
statistically signiﬁcant (χ2= 200.37, d.f.= 13, p < 0.001), explaining
33.5% (Nagelkerke R2) of the overall variance. Patients who
inaccurately reported ‘well-controlled’ asthma were 14 times more
likely to have taken 5–12 puffs or more of reliever in 1 day within
the previous 4 weeks (odds ratio (OR)= 14.02, 95% conﬁdence
interval (CI):4.19–47.00, p ≤ 0.001), nine times more likely to be
female (OR= 9.38, 95% CI: 6.23–14.13, p < 0.001), nearly nine times
more likely to have required oral corticosteroids for worsening
asthma in the previous year (OR= 8.80, 95% CI: 2.97–26.06, p ≤
0.001) and nearly four times more likely to have seen a respiratory
specialist more than a year ago rather than in the previous year
(OR= 3.63, 95% CI: 2.05–6.41, p < 0.001) (Table 6). There was a
signiﬁcant interaction between oral corticosteroid use and
respiratory specialist review. Among patients who had seen a
Table 2. Patient demographic characteristics by accurately versus
inaccurately reported ‘well-controlled’ asthma.
Characteristic Patient reported ‘well-
controlled’ asthma (N= 2582)
p Value*
Group A Group B
Accurately
reported
(n= 745)
Inaccurately
reported
(n= 1837)
Age, mean (SD) 50.0 (14.4) 51.4 (14.2) 0.02b
Age range (years), n (%)
18–29 74 (9.9) 171 (9.3) 0.04a
30–49 271 (36.4) 583 (31.7)
≥50 400 (53.7) 1083 (59.0)
Gender, n (%)
Female 267 (35.8) 1326 (72.2) <0.001a
Male 478 (64.2) 511 (27.8)
Body mass categoryc, n (%)
Underweight 12 (1.6) 21 (1.1) <0.001a
Normal 249 (33.4) 563 (30.6)
Overweight 300 (40.3) 601 (32.7)
Obese 184 (24.7) 652 (35.5)
Smoking status, n (%)
Current smoker 72 (9.7) 226 (12.3) 0.08a
Ex-smoker 219 (29.4) 566 (30.8)
Non-smoker 454 (60.9) 1045 (56.9)
Educationd, known
status, n (%)
(n= 651) (n= 1500)
PG or professional degree 30 (4.6) 63 (4.2) <0.001a
University degreee 224 (34.4) 508 (33.9)
Secondary educatione 278 (42.7) 772 (51.5)
Primary educatione 97 (14.9) 131 (8.7)
None 22 (3.4) 26 (1.7)
PG post graduate, SD standard deviation
*p Value of Group A versus Group B
Note: Percentages are column percentages
aχ2 test for independence
bMann–Whitney U test
cUnderweight BMI ≤18.49 kg/m2; normal BMI= 18.5–24.99 kg/m2; over-
weight BMI= 25–29.99 kg/m2; obese BMI ≥30 kg/m2
dEstimation of ‘well-controlled’ asthma by education reported as n (%) of
known status
eCompleted or some education
Table 3. Asthma symptoms and indicators of exacerbations by
accurately versus inaccurately reported ‘well-controlled’ asthma.
Patient reported ‘well-controlled’ asthma
(N= 2582)
p Value*
Group A Group B
Accurately
reported (n= 745)
Inaccurately reported
(n= 1837)
Asthma symptoms (past 7 days)
Daytime symptoms, n (%)
None 610 (81.9) 709 (38.6) <0.001a
1–2 days 135 (18.1) 500 (27.2)
≥ 3 days 0 628 (34.2)
Activity limitations due to asthma, n (%)
None 745 (100.0) 1371 (74.6) <0.001a
≥1 day 0 466 (25.4)
Night waking, n (%)
None 745 (100.0) 1311 (71.4) <0.001a
≥1 night 0 526 (28.6)
Reliever needed for symptoms, n (%)
Not used 607 (81.5) 713 (38.8) <0.001a
1–2 times 136 (18.2) 355 (18.3)
≥3 times 2 (0.3) 769 (41.9)
Highest number of puffs of reliever inhaler taken in 1 dayb, n (%)
0–4 736 (98.8) 1596 (86.9) <0.001a
5–12 or more 9 (1.2) 241 (13.1)
Acute exacerbations (past 12 months)
Oral corticosteroid use for worsening asthma, n (%)
None 610 (81.9) 1384 (75.4) <0.001a
1 98 (13.2) 263 (14.3)
≥2 37 (5.0) 188 (10.3)
Emergency department visit due to asthma, n (%)
None 694 (93.2) 1680 (91.5) 0.39a
1 37 (5.0) 111 (6.0)
≥2 14 (1.8) 46 (2.5)
Hospitalisation due to asthma, n (%)
None 730 (98.0) 1751 (95.4) 0.010a
1 14 (1.9) 64 (3.5)
≥2 1 (0.1) 21 (1.1)
*p Value of Group A versus Group B
aPearson’s χ2 test for independence
bHighest number of puffs of reliever inhaler use, in response to the
question: ‘In the past 4 weeks, what was the highest number of puffs in
1 day you took of the reliever inhaler?’ with response options 0, 1–4 puffs
and 5+ puffs
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respiratory specialist in the previous year, those who had not
required oral steroids in the previous 12 months were more likely
to accurately report ‘well-controlled’ asthma compared to patients
who had required oral steroid use. Among patients who had not
required oral steroids in the previous 12 months, those who had
seen a respiratory specialist in the previous year were more likely
to accurately report ‘well-controlled’ asthma compared to those
who had seen a respiratory specialist more than a year ago
(Table 6).
DISCUSSION
This research, to our knowledge, is the ﬁrst to explore the factors
that are associated with inaccurately reported ‘well-controlled’
asthma among a large cohort of adult patients who believe their
asthma is well controlled and are managed in primary care. In this
study, only 30.3% of patients had good asthma symptom control
based on GINA-deﬁned criteria despite receiving ﬁxed-dose
combination therapy. However, 60.4% of patients considered
their asthma to be ‘well controlled’, and of those patients, less
Table 4. Clinical characteristics by accurately versus inaccurately reported ‘well-controlled’, asthma.
Patient reported ‘well-controlled’ asthma (N= 2582) p Value*
Group A Group B
Accurately reported (n= 745) Inaccurately reported (n= 1837)
Patient-reported rhinitis symptoms, n (%) 480 (64.4) 1194 (65.1) 0.75a
Patient-reported prior inhaler review by HCPb, n (%) 348 (46.7) 1027 (56.0) <0.001a
Patient self-assessment of inhaler technique, n (%), known (n= 730) (n= 1816)
Very poor to poor 42 (5.8) 106 (5.8) 0.17a
Fair to average 94 (12.9) 287 (15.8)
Good to excellent 594 (81.4) 1423 (78.4)
Patient-reported respiratory specialist review (n= 620) (n= 1693)
Never 242 (39.0) 430 (25.4) <0.001a
In the previous year 107 (17.3) 230 (13.6)
More than a year ago 271 (43.7) 1033 (61.0)
Adherence to therapyc, n (%) (n= 724) (n= 1794)
Poor 219 (30.2) 569 (31.7) 0.70a
Borderline 45 (6.2) 101 (5.6)
Good 460 (63.5) 1124 (62.7)
Adherence to therapy in the Netherlandsd, n (%), known (n= 22) (n= 49)
Poor 7 (31.8) 5 (10.2) 0.06a
Borderline 5 (22.7) 9 (18.4)
Good 10 (45.5) 35 (71.4)
Patient-reported side effectse, n (%), known (n= 721) (n= 1793)
None 507 (70.3) 903 (50.4) <0.001a
1 146 (20.2) 434 (24.2)
2 52 (7.2) 276 (15.4)
≥3 16 (2.2) 180 (10.0)
Patient-reported oropharyngeal effectsg, n (%) known (n= 711) (n= 1766)
None 452 (63.6) 837 (47.4) <0.001a
1 137 (19.3) 444 (25.1)
2 88 (12.4) 275 (15.6)
3 34 (4.8) 210 (11.9)
Agreement to medication beliefs/perception items, n (%) known (n= 721) (n= 1796)
I need to take my inhaler(s) for my asthma to be well-controlled 460 (63.8) 1273 (70.9) 0.001a
I ﬁnd my inhaler easy to use 649 (90.0) 1616 (90.0) 0.98a
Taking regular asthma medication does not worry me 563 (78.1) 1422 (79.2) 0.55a
HCP health care practitioner
*p Value of Group A versus Group B
a Pearson’s χ2 test for independence
bIn the year before an iHARP asthma review
cNumber (%) calculated as percentage of patients from the UK, Italy, Spain, Sweden, France and Norway reported as n (%) of known status
dNumber (%) calculated as percentage of patients from the Netherlands
ePatient-reported side effects from preventer inhaler use, in response to the question: ‘Do you experience any of these side effects from your preventer
inhaler?’ with ‘yes’ or ‘no’ responses for the following side effects: continual sore mouth/throat; oral thrush; bruising; hoarse voice; abnormal weight gain and
cough. Patients could indicate more than one side effect
fPatient-reported oropharyngeal effects during inspiration phase of preventer inhaler use, in response to the question: ‘When you use your preventer inhaler,
do you feel a sensation at the back of your throat?; do you sometimes feel a need to cough?; do you feel your medication is deposited at the back of your
throat?’ with yes’ or ‘no’ response options. Patients could indicate more than one experience
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than one-third were accurate in reporting well-controlled asthma.
Our ﬁndings revealed that the incidence of accurately reported
‘well-controlled’ asthma was signiﬁcantly lower than that of
accurately reported ‘not-well-controlled’ asthma. The study
provided insight into the ‘silent’ burden of asthma from the
patient’s perspective and highlights the potential under-
recognition of the increased future risk associated with inaccu-
rately reported well-controlled asthma. Independent risk factors
associated with inaccurately reported ‘well-controlled’ asthma
were: having taken a maximum of 5–12 puffs or more of reliever
inhaler on at least one day within the previous 4 weeks; being
female; having seen a respiratory specialist more than a year ago
(rather than in the previous year) and having required oral
corticosteroids for worsening asthma in the previous year.
This study revealed a major discrepancy between patient-
reported and GINA-deﬁned control and a high incidence of
inaccurately reported ‘well-controlled’ asthma. While the discre-
pancy detected in this study is consistent with ﬁndings from
recent online surveys across Europe,17,18,24 Asia,19 Australia,12 Latin
America, Canada and the United States,13,15,17 this study is the ﬁrst
to identify factors associated with this discrepancy and highlights
the implications for practice. In summary, this study identiﬁed that
for patients who report good asthma control, 70% will be
inaccurate in their perception. From both the patient and HCP
perspective, this presents a challenge and questions the patient’s
ability to self-assess their asthma and then self-management.
From the HCP perspective, it questions the value of asking a
patient about their perception of their asthma control or relying
on the patient to report uncontrolled disease. It therefore
highlights the need to question the patient about their asthma
using validated asthma control questionnaires and to be proactive
in reviewing the patient’s asthma symptom control and future risk,
even when the patient does not recognise this need. This
potentially presents a series of HCP-patient relational issues.
Our study provided key insights into the signiﬁcant increased
future risk associated with under-recognition of poor asthma
control; that is, patients who overestimate their level of asthma
control are more likely to have experienced asthma exacerbations,
asthma-related hospitalisations, oropharyngeal effects and/or side
effects from asthma therapy, despite having received asthma care
and having had their inhaler technique checked in the past. This is
somewhat remarkable as these patients report a signiﬁcant
burden of symptoms and medication use: nighttime symptoms,
limitations in daily activities, oral corticosteroid use and high dose
and/or frequency of short-acting β-agonist (SABA) reliever use,
which can increase their future risk of adverse outcomes.3,19,35
Importantly, this study revealed that most patients who inaccu-
rately reported ‘well-controlled’ asthma are actually doing what
they need to do to manage their asthma in accordance with
guideline recommendations;3,4,36 that is, they have good medica-
tion adherence, hold strong beliefs about the need to take their
inhalers for their asthma to be well controlled and are not worried
about taking regular asthma medication. These ﬁndings suggest
that patients are ‘taking control’ of their asthma by doing what
they need to do; this ﬂags that they may be interpreting ‘asthma
control’ as a personal self-management behaviour (i.e. a verb)
rather than a disease outcome (i.e. a noun). This has implications
for asthma management practices and patient education, with the
need not only to address the perception discrepancy but also for
new terminology to promote a shared understanding of asthma
symptom control between patients and HCPs.
Identiﬁcation of independent risk factors for inaccurately
reported well-controlled asthma among adults with
moderate–severe asthma indicated that these factors are related
to patient demographics, rescue medication use and specialist
health care under-utilisation; being female, having taken 5–12
puffs or more of reliever inhaler in one day within the previous
4 weeks, having required oral corticosteroids for worsening
asthma in the previous year and having seen a respiratory
specialist more than a year ago rather than in the previous year. In
our study, a signiﬁcantly higher proportion of females inaccurately
reported ‘well-controlled’ asthma compared to males (83.2% vs.
51.7%, p < 0.001), which parallels previous ﬁndings that females
are more likely to have suboptimal levels of asthma control20 and
more likely to be at risk of making serious inhalation technique
errors that are linked to poor asthma control.37,38 Our ﬁndings add
to the body of ‘gender-related’ evidence, and suggest that the
self-management tools currently available are not meeting the
needs across the genders. There is clearly a need to focus more on
giving females the tools that will enable them to become better
self-managers of their asthma.
In this study, patients who overestimated their level of asthma
control were 14 times more likely to have taken a maximum of
5–12 puffs or more of SABA reliever per day in the previous
Table 5. Univariable associations between patient characteristics and inaccurately reported ‘well-controlled’ asthma.
Reference category Category Odds ratio (95% CI) p Value
Age group >50 years 18–50 years 0.80 (0.68–0.95) 0.011
Gender Male Female 4.65 (3.88–5.57) <0.001
Body mass index Obese Underweight/
normal weight
0.63 (0.51–0.79) <0.001
Education completed PG/Professional/University degree Secondary education 1.24 (1.01–1.51) 0.040
Highest number of puffs of reliever taken in 1 daya 5–12 or more 0–4 0.08 (0.04–0.16) <0.001
Oral corticosteroid use for worsening asthmab ≥1 0 0.68 (0.55–0.84) <0.001
Hospitalisation due to asthmab ≥1 0 0.42 (0.24–0.74) 0.002
Inhaler review by HCPb Yes No 0.69 (0.58-0.82) <0.001
Respiratory specialist review More than a year ago In the previous year 0.56 (0.43–0.74) <0.001
Side effects from preventer inhaler use ≥1 0 0.43 (0.36–0.52) <0.001
Oropharyngeal effects during inspiration phase ≥1 0 0.52 (0.43–0.62) <0.001
Need to take inhaler(s) for asthma to be
‘well-controlled’
Agree Disagree 0.72 (0.60–0.87) 0.001
HCP health care practitioner, PG post graduate
aIn the 4 weeks before an iHARP asthma review consultation
bIn the year before an iHARP asthma review consultation
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4 weeks. This dose of SABA reliever is by far above what is
expected and recommended in practice guidelines; that is, 1–2
puffs of SABA as needed for symptom relief during maintenance
treatment in asthma.3,4 Overuse of SABA may itself potentially
contribute to poor asthma control,39 increased risk of exacerba-
tions40,41 and fatal asthma.42 It has been well documented that
with chronic or high-dose exposure, β-agonists demonstrate
proinﬂammatory effects, rebound bronchoconstriction and toxi-
city that can masquerade as worsening asthma.43 Further, where
overuse is associated with rebound bronchoconstriction, patients
will often respond by taking even more SABA medication, thereby
entering a vicious cycle of increasing use and progressively
worsening symptoms.43,44 Our ﬁndings indicate a complete
misunderstanding of the use of SABA relievers or what we are
asking as HCPs, and a lack of awareness of the potential for SABA
toxicity to be a signiﬁcant contributor to poor asthma control. It
highlights the deﬁciency in asking simply on how many times/
days per week a patient has used their SABA reliever over the past
4 weeks. Our ﬁndings suggest a need for reconsideration of
guideline questions that refer to SABA use, and better education
of patients, particularly those who have used high doses in the
emergency department for acute asthma and continue to use
high doses when they have breakthrough symptoms thereafter. In
addition, patients who had overestimated their control level were
almost nine times more likely to have used oral steroids for
worsening symptoms in the previous 12 months reﬂecting a
‘rescue’ rather than a ‘prevention’ of symptoms approach to
asthma management, which is consistent with previous ﬁndings,19
and not without consequences.45,46
Inaccurately reported ‘well-controlled’ asthma was almost four
times more likely in patients who had seen a respiratory specialist
more than a year ago rather than in the previous year. Our study
found that accurately reported ‘well-controlled’ asthma was
signiﬁcantly more likely among patients who had seen a
respiratory specialist in the previous year versus more than a
year ago, and even more likely among a subset of patients who
had not required oral steroids in the previous 12 months,
suggesting that specialist referral in the previous year may help
improve the discrepancy between patient-perceived and actual
disease control. While specialist referral can be effective in
improving asthma management, reducing the risk of severe
exacerbations and reducing the number of hospitalisations and
the risk of future hospitalisations,47 there are many barriers that
may impede the referral process. These need to be addressed and
include overestimation of patients’ actual asthma control by
physicians, lack of awareness of guidelines by physicians, lack of
adherence to referral guidelines by physicians, communication
difﬁculties between patients and physicians with disparities
between patient expectations and experiences with HCPs,
ﬁnancial disincentives for practice stakeholders and low avail-
ability of specialists to provide advanced patient care.9,20,24,48
Importantly, this study suggests that patient’s perception of their
level of asthma control is not linked to preventer medication taking
behaviour, as there was no signiﬁcant difference in adherence rates
to ﬁxed-dose combination therapy using the 5-item Medication
Adherence Report Scale (MARS) between patients who accurately
and inaccurately reported well-controlled asthma. Patient’s percep-
tion of their level of asthma control could be inﬂuenced by other
factors not considered in the analysis, such as ownership of a
current written asthma action plan, inhaler technique, knowledge
about asthma and trigger factors, asthma-related quality of life,
illness perceptions or psychological dysfunction.9,28,32 Another
possible explanation for our ﬁndings, is that the MARS may have
poor precision and overestimated adherence rates to preventer
medication among this patient population.
The strengths of the study are its large sample size, observa-
tional design, real-world evidence, global focus and comprehen-
siveness, including objective and patient-reported outcomes. This
study design enabled the exploration of a heterogeneous,
representative population of general practitioner-managed
patients with an asthma diagnosis, who were prescribed
combination preventer therapy; as this is the most commonly
used treatment for asthma, it is likely the ﬁndings are
generalisable in primary care. There are some potential limitations
Table 6. Logistic regression predicting likelihood of inaccurately reporting ‘well-controlled’ asthma.
Reference category Category B Odds ratio (95% CI) p Value
Age group 18–50 years >50 years 0 1.00 (0.66–1.52) 1.00
Gender Male Female 2.24 9.38 (6.23–14.13) <0.001
Body mass index Underweight/
normal weight
Obese −0.04 0.96 (0.64–1.45) 0.84
Education level Secondary education PG/Professional/University degree −0.10 0.91 (0.60–1.370 0.64
Highest number of puffs of reliever taken in
1 daya
0–4 5–12 or more 2.64 14.02 (4.19–47.00) <0.001
Oral corticosteroid use for worsening asthmab 0 ≥1 2.18 8.80 (2.97–26.06) <0.001
Hospitalisation due to asthmab 0 ≥1 −0.34 0.71 (0.22–2.31) 0.57
Inhaler review by HCPb No Yes −0.11 0.90 (0.59–1.36) 0.61
Respiratory specialist review In the previous year More than a year ago 1.29 3.63 (2.05–6.41) <0.001
Side effects from preventer inhaler use 0 ≥1 0.35 1.42 (0.93–2.18) 0.11
Oropharyngeal effects during
inspiration phase
0 ≥1 0.29 1.33 (0.88–2.01) 0.18
Need to take inhaler(s) for asthma to be
‘well-controlled’
Disagree Agree −0.02 0.98 (0.62–1.56) 0.93
Oral corticosteroid use*Respiratory
specialist review
0 ≥1 −1.97 0.14 (0.04–0.49) 0.002
In the previous year More than a year ago
aIn the 4 weeks before an iHARP asthma review
bIn the year before an iHARP asthma review
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to this study, which are associated with the cross-sectional study
design, which does not allow us to infer cause and effect, and a
reliance on patient recall for self-reported symptoms, exacerba-
tions and medication behaviour that may have been under- or
over-stated by patients. Additionally, although there were criteria
to exclude people with chronic obstructive pulmonary disease
(COPD), and given that many people were aged 50 years or more
with a past or current history (and a greater risk of COPD), it may
have been possible that people with both asthma and COPD were
included and could have biased the results. Another limitation of
this study relates to the use of an international dataset and
possible confounding caused by inter-country differences in how
disease outcomes are measured and recorded (e.g. the Nether-
lands does not use the MARS to assess adherence). A further
limitation of this study relates to the high variability in responses
caused by recruitment over several countries. Finally, while
signiﬁcant predictors were identiﬁed in our multivariate logistic
regression model, the overall variance explained by the model
(33.5%) was relatively low, suggesting other factors not considered
in the current analyses may correlate with inaccurately reported
‘well-controlled’ asthma and reiterating the need for further
research in this area. Despite these limitations, this research
provided new insight by utilising a structured in-depth asthma
review approach and helped in identifying several risk factors
associated with inaccurately reported ‘well-controlled’ asthma,
which when addressed may help reduce the discrepancy between
actual and perceived disease control, improve the incidence of
well-controlled asthma and reduce the burden of disease.
The study identiﬁed factors associated with patient’s over-
estimation of their actual level of asthma and highlighted the
signiﬁcant hidden burden associated with under-recognition of
poor asthma control, on the part of the patient. It raises the
question about the causes for this under-recognition and questions
the way in which we ask patients about asthma control. While
some of the factors associated with under-recognition may be
modiﬁable, there is an urgent need for targeted interventions that
include new strategies, measures and terminology designed to
address the continuing discrepancy between perceived and actual
disease control. Future qualitative research should explore the
causes for under-recognition of poor asthma control as unless we
are able to support patients to better align their perception of their
asthma with their actual level of asthma control, we will continue
to face some fundamental challenges with the management of
asthma, and the increased risk of adverse outcomes associated
with the poor self-management of this chronic respiratory disease.
METHODS
Data source
This historical, cross-sectional observational study used anonymised patient
data from the iHARP database, an international database comprising
anonymised data from practices receiving the iHARP asthma review service.
Data were collected prospectively between June 2011 and December 2014
in participating primary care practices in Australia and seven European
countries (the United Kingdom (UK), Italy, Spain, France, the Netherlands,
Norway and Sweden). The data included patient demographics and results
from respiratory reviews led by trained practitioners and asthma ques-
tionnaires completed by patients on the day of the iHARP asthma review. For
patients assessed within the UK, these data were linked to clinical, diagnostic
and prescribing information from electronic medical records.
Each of the participating sites obtained ethics approval for the iHARP
asthma review service according to their country-speciﬁc requirements. All
participants provided informed consent. The study was registered with the
European Network of Centres for Pharmacoepidemiology and Pharma-
covigilance (ENCEPP) (as ENCePP/SDPP/9651).
Cohort deﬁnition
To be eligible for iHARP review, patients had to have a current diagnosis of
asthma, received ≥2 ﬁxed-dose combination inhaled corticosteroid and
long-acting β2 agonist (FDC ICS/LABA) therapy in the year before the
review, and their data had to meet standards of the International Primary
Care Respiratory Group,49 Quality and Outcomes Framework recommen-
dations50 and GINA strategy report at the time of data collection.51 Patients
were excluded if they had a diagnosis of COPD or any other chronic
respiratory disease other than asthma, or if they were receiving long-term
systemic asthma treatment (e.g. maintenance oral corticosteroids,
theophylline, leukotriene receptor antagonists or anti-IgE therapy), or oral
corticosteroids and/or antibiotics for a lower respiratory condition in the
2 weeks before data collection. Our study cohort was restricted to the
subset of patients from the database who were at least 18 years of age
from participating practices across seven European countries.
Study data and assessments
Demographics and data from patient-completed asthma questionnaires
were obtained from the iHARP database. Asthma control was assessed
using the four GINA criteria at the time, which asked patients if they
experienced the following during the week preceding the review visit:
daytime symptoms (more than twice/week); any night wakening due to
asthma; need reliever inhaler (more than twice/week); any limitation in
daytime activity. The presence of these four criteria determined the
asthma control category as follows: none of the above (controlled); 1 or 2
of the above (partially controlled); 3 or 4 of the above (uncontrolled).51
Patient perceptions of their recent asthma control were elicited by
asking the patient to respond to the following question: ‘In the past
4 weeks, did you believe that your asthma was ‘well controlled’?’ with ‘yes’
or ‘no’ response options. Patients were categorised in Group A if they
indicated they believed that their asthma was ‘well controlled’ AND had
controlled asthma as assessed by GINA-deﬁned criteria. Patients were
categorised in Group B if they indicated they believed that their asthma
was ‘well controlled’ BUT had partially controlled or uncontrolled asthma
according to GINA-deﬁned criteria.
Self-reported rhinitis symptoms were assessed with a single question
derived from the Allergic Rhinitis and its Impact on Asthma (ARIA) and
IPCRG deﬁnition of rhinitis;52,53 ‘Do you have any of these symptoms: itchy,
runny, blocked nose or sneezing when you don’t have a cold?’, with
responses ranging from, 0 (‘no’), 1 (‘occasionally and little bother’), 2
(‘occasionally but quite a bother’), 3 (‘most days but little bother’), or 4
(‘most days and a lot of bother’). Responses 1 and 3 were classiﬁed under
‘mild’ rhinitis and responses 2 and 4 under ‘moderate–severe’ rhinitis.
All patients were asked if their inhaler technique had been reviewed in
the previous year by an HCP, and patients were asked to self-assess their
inhaler technique using a Likert scale with scores ranging from 1 (‘I think
my inhaler technique is very poor’) to 6 (‘I think my inhaler technique is
excellent’). Patients were also asked if they had been reviewed by a
specialist respiratory doctor or nurse outside the practice with three
response options; ‘in the previous year’, ‘more than a year ago’ or ‘never’.
Beliefs and perceptions about asthma therapy were assessed with three
items from the Beliefs about Medicines Questionnaire that were adapted
for use in asthma:54 ‘I need to take my inhaler(s) for my asthma to be ‘well
controlled’; ‘I ﬁnd my inhalers easy to use’ and ‘Taking regular asthma
medication does not worry me,” with ratings on a 6-point Likert scale from
1 (strongly agree) to 6 (strongly disagree).
Self-reported adherence to maintenance therapy was assessed for
patients from the UK, Italy, Spain, France, Norway and Sweden using the
MARS.55 For patients from the Netherlands, adherence to maintenance
therapy was assessed with the question, ‘Do you ever forget your
prevention inhalation medication?’ Adherence was categorised as poor for
responses of ‘very often’ or ‘always’; borderline for responses of ‘now and
then’ or ‘regularly’ and good for responses of ‘never’ or ‘rarely’.
Patient-reported experiences during the inspiration phase of preventer
inhaler use (i.e. feeling a sensation at the back of the throat, a need to
cough and/or of medication being deposited at the back of the throat),
side effects from preventer inhaler medications (i.e. continual sore mouth/
throat, oral thrush, bruising, hoarse voice, cough and abnormal weight
gain) and the highest number of puffs of reliever inhaler taken in 1 day in
the previous 4 weeks were recorded during the iHARP review on the
patient-completed questionnaire.
Exacerbations were identiﬁed by one of the following patient-reported
outcomes: hospital admission with breathing or chest problems; emer-
gency department visit related to asthma; or an acute course (5–10 days)
of oral corticosteroids for worsening asthma. The number of exacerbations
was taken from the 12-month period preceding the iHARP review.
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Data analysis
Analyses were performed using SPSS (IBM® SPSS® Statistics) Version 24.
Characteristics of patients who accurately reported ‘well-controlled’
asthma (Group A) were compared to those of patients who inaccurately
reported ‘well-controlled’ asthma (Group B). Continuous variables that
were normally distributed were compared using Student’s t test and the
Mann–Whitney U test was used for continuous variables that were not
normally distributed. Categorical variables were compared using Pearson’s
χ2 test. Univariable logistic regression models, with a dichotomised
indicator variable (yes/no) as the dependent variable and each patient
characteristic as an explanatory (or predictor) variable, were ﬁrst used to
identify characteristics associated with inaccurately reported ‘well-con-
trolled’ asthma. Indicators of asthma symptoms and asthma control were
not tested using univariable logistic regression because they were used to
deﬁne the dependent variable. Intercorrelations among the predictor
variables were then tested using Tolerance values, and those with high
intercorrelations were not included in subsequent analyses. Demographic
and clinical characteristics associated with inaccurately reported ‘well-
controlled’ asthma in the univariable model (p < 0.05) were then entered
into a multivariable regression model to produce a ﬁnal list of non-collinear
independently associated variables. Interactions between different vari-
ables were tested, and those that did not improve the model were not
included. The goodness of ﬁt of the logistic regression model was
conﬁrmed by the Hosmer and Lemeshow test. A two-tailed signiﬁcance
level of 0.05 was used for all statistical procedures.
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